Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide withdrawal versus continuation after reaching target dose in adults with overweight or obesity
MOH_2018-02-20_002187Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2018
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity and Overweight comparing Semaglutide continuation with Placebo after semaglutide run-in (2 arms). Primary endpoint: Change in body weight. Started Feb 2018; status: completed.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on MOH_2018-02-20_002187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-02-20_002187.